Piper Sandler Upgrades Axsome Therapeutics to Overweight, Raises Price Target to $90
Portfolio Pulse from richadhand@benzinga.com
Piper Sandler analyst David Amsellem has upgraded Axsome Therapeutics from Neutral to Overweight and raised the price target from $70 to $90.

August 08, 2023 | 8:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axsome Therapeutics has been upgraded from Neutral to Overweight by Piper Sandler, with a raised price target from $70 to $90.
The upgrade from Neutral to Overweight by Piper Sandler indicates a positive outlook for Axsome Therapeutics. The raised price target from $70 to $90 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100